Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Biologic Response Modifiers

Identification of Five Structurally Unrelated Quorum-Sensing Inhibitors of Pseudomonas aeruginosa from a Natural-Derivative Database

Sean Yang-Yi Tan, Song-Lin Chua, Yicai Chen, Scott A. Rice, Staffan Kjelleberg, Thomas E. Nielsen, Liang Yang, Michael Givskov
Sean Yang-Yi Tan
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
School of Biological Sciences, Nanyang Technological University, Singapored
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Song-Lin Chua
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), National University of Singapore, Singaporeb
Faculty of Science, National University of Singapore, Singaporec
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yicai Chen
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. Rice
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australiaf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Staffan Kjelleberg
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
Centre for Marine Bio-Innovation and School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australiaf
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas E. Nielsen
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
Department of Chemistry, Technical University of Denmark, Lyngby, Denmarkg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Yang
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
School of Biological Sciences, Nanyang Technological University, Singapored
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Givskov
Singapore Centre on Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singaporea
Costerton Biofilm Center, Department of International Health, Immunology and Microbiology, Panum Institute, University of Copenhagen, Copenhagen, Denmarke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.00955-13
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Bacteria communicate by means of small signal molecules in a process termed quorum sensing (QS). QS enables bacteria to organize their activities at the population level, including the coordinated secretion of virulence factors. Certain small-molecule compounds, known as quorum-sensing inhibitors (QSIs), have been shown to effectively block QS and subsequently attenuate the virulence of Pseudomonas aeruginosa, as well as increasing its susceptibility to both antibiotics and the immune system. In this study, a structure-based virtual screening (SB-VS) approach was used for the discovery of novel QSI candidates. Three-dimensional structures of 3,040 natural compounds and their derivatives were obtained, after which molecular docking was performed using the QS receptor LasR as a target. Based on docking scores and molecular masses, 22 compounds were purchased to determine their efficacies as quorum-sensing inhibitors. Using a live reporter assay for quorum sensing, 5 compounds were found to be able to inhibit QS-regulated gene expression in P. aeruginosa in a dose-dependent manner. The most promising compound, G1, was evaluated by isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomic analysis, and it was found to significantly affect the abundance of 46 proteins (19 were upregulated; 27 were downregulated) in P. aeruginosa PAO1. It specifically reduced the expression of several quorum-sensing-regulated virulence factors, such as protease IV, chitinase, and pyoverdine synthetases. G1 was also able to reduce extracellular DNA release and inhibited the secretion of the virulence factor, elastase, whose expression is regulated by LasR. These results demonstrate the utility of SB-VS for the discovery of target-specific QSIs.

INTRODUCTION

Bacteria communicate via a phenomenon termed quorum sensing (QS) in which they secrete chemical signal molecules, termed autoinducers, into their surrounding environment (1). The concentration of these signal molecules increases locally as a result of increasing cell density, and upon reaching a threshold level (when the population is “quorate”), the population activates a coordinated cellular response, such as the production of virulence factors and growth as a biofilm community (2, 3).

Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium that is responsible for many opportunistic and nosocomial infections (4), and chronic infection by P. aeruginosa is the leading cause of death of cystic fibrosis patients (5). P. aeruginosa has three main QS systems. The first two QS systems, LasR-LasI and RhlR-RhlI, are based on the LuxR-LuxI homologues of Vibrio fischeri (1), which make use of acyl homoserine lactones (AHLs) as signal molecules (6). The AHL synthases are LasI and RhlI, which produce N-(3-oxododecanoyl)-l-homoserine lactone (OdDHL) (7) and N-butanoyl homoserine lactone (BHL), respectively (8). The receptor for OdDHL is the LasR protein (9), while the receptor for BHL is the RhlR protein.

Together, the las and rhl QS systems regulate a host of virulence factors, such as exoproteases (an example being elastase), siderophores, and toxins (10, 11). The third signaling system utilizes another kind of signal molecule, 2-heptyl-3-hydroxy-4-quinolone, that has been termed the Pseudomonas quinolone signal (PQS) and is able to affect the expression of Las- and Rhl-controlled genes (12). LasR is an attractive target for QS inhibition, since LasR controls the other QS circuits (namely, Rhl and PQS) within the P. aeruginosa hierarchy (13). The las and rhl systems are at the top and bottom of the hierarchy, respectively, while the PQS system intervenes between them.

Because QS controls the expression of multiple virulence factors in different bacteria, blocking of QS would be vital in attenuating the virulence of pathogenic bacteria. During the last decade, the QS system has been proposed as a target for developing next-generation antimicrobial agents. The rationale for interrupting bacterial communication rather than inhibiting growth is that QS inhibitors (QSIs), by targeting nonessential processes, are shown to not exert strong selective pressure for the evolution of resistance mechanisms compared to the conventional growth-inhibitory compounds (14, 15).

The conventional approach to identifying QSIs is to use biosensor systems which often fuse a QS-regulated promoter to the lux, gfp, or lacZ reporter gene (16, 17, 18). A wide range of QSIs were identified by the use of these biosensor systems (19). However, QSIs identified through the use of biosensors might not be target specific and have some potential risk in their application. QS regulation is integrated into the complex bacterial regulation networks which also include nucleotide signaling (e.g., cAMP and c-di-GMP) (20), iron signaling (21), phosphate signaling (22), and so on. Thus, QSIs identified through the use of biosensor systems might actually target other regulators which also affect QS. This brings the risk that these QSIs might be able to induce virulence factors regulated by other regulation networks even though they can inhibit QS. Therefore, a computer-aided method for the rational identification of QSIs may provide a means of discovering QSIs with increased target specificity.

In contrast to the conventional lab-based screens, some have utilized a computer-based approach to drug screening known as structure-based virtual screening (SB-VS). SB-VS can be defined as a method to computationally screen large compound libraries for molecules that bind targets of known structure and then test experimentally those predicted to bind well (23). Recent successes of this approach include inhibitors against the apoptosis regulator Bcl-2, Hsp90, G-protein-coupled receptors, and metalloenzymes (24).

With the recent availability of crystal structures of bacterial QS receptor proteins, such as LasR of Pseudomonas aeruginosa (25) and TraR of Agrobacterium tumefaciens (26), SB-VS has become a viable option for QSI discovery. Yang et al. (27) used an SB-VS approach in the search for novel inhibitors of the LasR protein of P. aeruginosa (27). A total of 147 compounds from the SuperNatural (28) and SuperDrug (29) databases were selected for the screening through a rational approach, based on two-dimensional (2D) structure similarity to known QSIs. These compounds were then subjected to molecular docking against the ligand-binding domain of LasR, and the top-scoring “hits” were then tested for biological activity. Several recognized drugs, such as salicylic acid, were identified as QSIs.

In this study, we investigated the use of a computer-aided approach for the discovery of novel QS inhibitors of the P. aeruginosa LasR protein. The DG-AMMOS software program (30) was used to convert 2D chemical structures into 3-dimensional (3D) conformations based on distance geometry. The entire library of compounds from TimTec's Natural Derivatives Library, 3,040 in all, was converted using DG-AMMOS to 3D structures and then used for the molecular docking process within the Molegro Virtual Docker (MVD) program. Twenty-two small-molecule QSI candidates were ordered and tested for quorum-sensing-inhibition efficacy. Five of these compounds were found to inhibit the P. aeruginosa LasR QS system in a dose-dependent manner, while only one compound, 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1), was found to inhibit LasR specifically in a heterologous Escherichia coli reporter strain. Isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomic analysis was then used to study the protein expression changes in P. aeruginosa PAO1 as a result of G1 addition.

MATERIALS AND METHODS

Structure-based virtual screening.The process work flow for the structure-based virtual screening is based largely on the methods used previously (27), with the major difference being the usage of DG-AMMOS for the conversion of the entire compound library into 3D structures.

Protein structure file and ligand database.The X-ray crystal structure of the P. aeruginosa LasR ligand-binding domain (LBD) bound to its natural ligand, OdDHL, (25), was downloaded from the Protein Data Bank website (PDB ID 2UV0) and used for structure-based virtual screening. For the SB-VS, the structures of 3,040 ligands from TimTec's (TimTec LLC, Newark, DE) Natural Derivatives Library were downloaded from TimTec's website. These structures were in 2D coordinate structure-data file (SDF) format, and hence, an automated program, DG-AMMOS (30), was used to convert the entire library of 2D chemical structures into 3D conformations based on distance geometry and automated molecular mechanics optimization. Thus, the entire library of compounds from TimTec's Natural Derivatives Library, 3,040 in all, was converted to 3D structures and used for the subsequent molecular docking procedures. 2D structures of reference compounds were drawn manually using the software program Marvin Sketch v. 5.9.0 (ChemAxon Ltd., Hungary) and then saved as 2D SDF files. The SDF files were merged into a single SDF file using the program OpenBabel v. 2.3.1 (OpenEye Scientific Software) and likewise converted to 3D structures through the use of DG-AMMOS.

Molecular docking.The Molegro Virtual Docker (MVD) v. 5.0.0 software program (31) (Molegro ApS, Denmark) was used for the automated docking procedure. MVD uses the MOLDOCK algorithm, which was able to correctly identify the binding mode of ligands with 87% accuracy, which was higher than that of the modern docking programs GLIDE (32) and Surflex (33). From the LasR PDB structure file, only the E monomer LBD in a complex with the OdDHL ligand, OHN 1169 [E], was imported into the MVD workspace. Water molecules were not imported, and default parameters were used for the import process.

For the docking process, a docking template was first generated based on the interaction of the native OdDHL ligand with the LasR ligand-binding domain. This template included steric, hydrogen donor, hydrogen acceptor, and ring contributions. Template docking was then carried out using Ligand Evaluator for scoring of the poses and Moldock Optimizer for the search algorithm. The docking was constrained to a sphere of 9-Å radius centered on the OdDHL ligand and its corresponding cavity. For molecular docking, 3,040 ligands from the Natural Derivative Library and 7 reference ligands (OdDHL reference ligand along with 7 known QSIs) were used. Each compound was docked for 10 iterations in order to obtain an energy-minimized protein-ligand conformation. One pose was generated by each run, and the resulting poses were ranked. The parameters used for import of molecules and docking in MVD are specified in Table S3 in the supplemental material. The software program LIGPLOT v. 4.5.3 (34) was used to map the interactions between QSI lead compounds and the residues within the LasR protein LBD. PyMOL v. 1.4 (Schrodinger, LLC) was used for preparation of 3D images.

Selection of QSI candidates.Compounds from the TimTec Natural Derivative Library were docked against the LasR LBD in MVD and subsequently ranked according to their rerank score, molecular mass in Daltons, and calculated ligand efficiency (computed as rerank score divided by the number of heavy atoms in a compound). In order to select for small-molecule QSI candidates, only compounds having a molecular mass less than 200 Da and a rerank score below −60 were selected. The rerank score value of −60 was used as a cutoff because known QSIs that were docked in MVD generally had a score below −60. A total of 22 QSI candidates were selected and were purchased from TimTec, Inc. (TimTec LLC, Newark, DE). Compounds were shipped in glass vials in powder form, and these were dissolved in dimethyl sulfoxide (DMSO) prior to in vitro experiments. The purity (>90%) and identity of all compounds were confirmed by high-performance liquid chromatography-mass spectrometry (electrospray ionization) [HPLC-MS (ESI)] on a Waters Aquity reverse-phase ultraperformance liquid chromatography (RP-UPLC) system equipped with a diode array detector using an Aquity UPLC BEH C18 column (diameter, 1.7 μm; 2.1 by 50 mm; column temperature,65°C; flow, 0:6 ml/min). Eluents A (0.1% HCO2H in H2O) and B (0.1% HCO2H in acetonitrile [MeCN]) were used in a linear gradient (5% B to 100% B) in a total run time of 2.6 min. The liquid chromatography (LC) system was coupled to an SQD (single quadrupole detector) mass spectrometer.

Bacterial strains.To determine the QSI activity of the compounds selected from the virtual screening, the following P. aeruginosa and E. coli monitor strains were used (Table 1). These monitor strains have their respective promoters fused to an unstable GFP (green fluorescent protein) that has a C-terminal oligopeptide extension containing the amino acids ASV [gfp(ASV)]; this causes the GFP to be more susceptible to degradation by housekeeping proteases and therefore to have a short half-life. As such, unstable gfp(ASV) allows for monitoring of temporal QS-regulated gene expression (35). For proteomic analysis, we used the sequenced P. aeruginosa PAO1 wild-type strain obtained from the Pseudomonas Genetic Stock Center (PAO0001).

View this table:
  • View inline
  • View popup
Table 1

P. aeruginosa and E. coli strains used in this study

Growth media and conditions.The bacteria strains were grown in either ABTGC (see below) or Luria-Bertani (LB) medium.

ABTGC medium.ABTGC medium is AB minimal medium (64) containing 2.5 mg/liter thiamine, supplemented with 0.2% (wt/vol) glucose and 0.2% (wt/vol) Casamino Acids; LB medium contains 1.0% tryptone, 0.5% yeast extract, and 1.0% NaCl, adjusted to pH 7.0. Overnight cultures were grown for 16 h at 37°C and shaken at 180 rpm. Selective media were supplemented with ampicillin (100 mg liter−1) or gentamicin (60 mg liter−1) where appropriate.

P. aeruginosa QS inhibition assays.Test compounds were dissolved in 100% DMSO and mixed with ABTGC medium, after which they were added to the first column of wells of a 96-well microtiter plate (Nunc) to give a final concentration of 100 μM in a final volume of 200 μl. One hundred microliters of ABTGC medium was then added to the remaining wells in the plate, and serial 2-fold dilutions of the inhibitors were made by adding 100 μl of the preceding inhibitor-containing well to the subsequent one. The final column was left without inhibitor as a control. Next, an overnight culture of the P. aeruginosa lasB-gfp(ASV) strain, grown in LB medium at 37°C with shaking, was diluted to an optical density at 600 nm (OD600) of 0.2, and 100 μl of bacterial suspension was added to each well of the microtiter plate. Hence, inhibitor concentrations ranged from 50 μΜ to 0.78125 μM across the plate, in a volume of 200 μl. The microtiter plate was incubated at 37°C in a Tecan Infinite 200 Pro plate reader (Tecan Group Ltd., Männedorf, Switzerland). GFP fluorescence (excitation at 485 nm, emission at 535 nm) and cell density (OD600) measurements were collected at 15-min intervals for at least 14 h. The P. aeruginosa Rhl and Pqs inhibition assays were performed in a manner similar to that for the LasR inhibition assay.

E. coli competition assay between QSI compounds and OdDHL.The E. coli lasB-gfp(ASV) reporter strain was used for the competition assay, which was performed in a manner similar to that for the P. aeruginosa LasR inhibition assay. OdDHL and the QSI to be studied were added to the wells of a microtiter plate containing ABTGC medium. Wells without OdDHL and/or QSI were included as controls. An overnight culture of the E. coli lasB-gfp(ASV) strain, grown in LB medium at 37°C with shaking, was diluted to an OD600 of 0.2, and 100 μl of bacterial suspension was added to each well of the microtiter plate. Hence, the plate contained OdDHL at concentrations ranging from 20 nM to 320 nM and QSI at concentrations ranging from 3.125 μM to 50 μM (including control wells without OdDHL, QSI, or both). GFP and OD600 readings were obtained as described above for the P. aeruginosa LasR inhibition assay.

Inhibition of the rhl and pqs QS systems in wild-type PAO1 and a PAO1 lasR mutant.Wild-type P. aeruginosa PAO1 strains harboring either the rhlA-gfp(ASV) reporter or the pqsA-gfp(ASV) reporter and a P. aeruginosa PAO1 lasR mutant harboring either the rhlA-gfp(ASV) reporter or the pqsA-gfp(ASV) reporter were used for this experiment (see Table 1 for strain information). Overnight cultures of these four strains were diluted 100-fold in ABTGC medium within 96-well microtiter plates to a final volume of 200 μl per well. Each of the five QSIs was added in triplicate to a final concentration of 50 μM. DMSO at 0.5% was used as a negative control. The microtiter plate was incubated at 37°C in a Tecan Infinite 200 Pro plate reader, where GFP and OD600 readings were measured at 15-min intervals.

Glass-slide biofilm assay for observation of eDNA release.The glass-slide biofilm assay was performed as previously reported (36). Briefly, gfp-tagged P. aeruginosa PAO1 biofilms were cultivated in 50 ml BD Falcon tubes containing 15 ml ABTG medium. A sterile 24-mm by 60-mm glass cover slide was inserted into each Falcon tube for supporting biofilm growth. G1 (10 μM) was added to the biofilm medium to examine its impact on P. aeruginosa PAO1 biofilm formation. DMSO was added alone to the medium as a control. Biofilms were incubated at 37°C without shaking. A 2 μM concentration of propidium iodide (Sigma-Aldrich) was added to biofilm cultures to stain extracellular DNA (eDNA) for 5 min after 24-h growth. After that, biofilm-attached glass slides were observed by confocal laser scanning microscopy (CLSM).

iTRAQ-based proteomics analyses for G1.Isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomic analysis was used to study the changes in protein expression of the P. aeruginosa PAO1 strain in response to the addition of 25 μM G1. Proteomics experiments were performed at the Proteomic Core Facility of the Biological Research Center, School of Biological Sciences, Nanyang Technological University, Singapore. A full description of the proteomics work flow is included as supplemental material.

Elastase assay.P. aeruginosa PAO1 wild type and an elastase-negative lasI rhlI mutant were cultivated in LB medium overnight at 37°C with shaking. Overnight cultures were diluted 1:100 to 5 ml ABTGC medium and incubated at 37°C with shaking. Compound G1 was supplemented to the PAO1 cultures at final concentrations of 0, 50, and 100 μM. After 2 h of incubation, 0.8-ml culture supernatants were sampled by centrifugation (18,000 × g, 4 min) and filtration through 0.2-μm filters. Elastase activity of P. aeruginosa culture supernatants was measured by using the EnzChekElastase assay kit (Invitrogen), which uses BODIPY fluorophore (FL)-labeled DQ elastin conjugate as the substrate of elastase. The BODIPY FL-labeled DQ elastin conjugate, when cleaved by elastase enzyme, yields highly fluorescent fragments. Fluorescence was recorded every 6 min for 180 min by using a Tecan Infinite 200 Pro plate reader (excitation at 490 nm, emission at 520 nm).

RESULTS

Structure-based virtual screening for QSIs.Molecular docking was first performed using the reference ligand OdDHL and several known LasR inhibitors against the ligand-binding domain of LasR (PDB ID 2UV0) in MVD. These compounds and their structures are shown in Fig. 1, and their docking scores (see Table S1 in the supplemental material) provide a comparison for the selection of potential QSI candidates from the library compound screening.

Fig 1
  • Open in new tab
  • Download powerpoint
Fig 1

The chemical structures of the reference ligand, OdDHL, and other known QS inhibitors used as comparisons for the structure-based virtual screening. References are given after for each compound. (A) 3-Oxo-C12-HSL (OdDHL) (7); (B) patulin (49); (C) salicylic acid (27); (D) 3-oxo-C12-(2-aminophenol) (63); (E) furanone C30 (14); (F) 4-nitropyridine-N-oxide (18); (G) nifuroxazide (27); (H) chlorzoxazone (27).

A 3D structural database containing 3,040 structures of compounds from TimTec's Natural Derivatives Library was created using DG-AMMOS (30), after which it was docked against the ligand binding domain of LasR. Twenty-two compounds having a rerank score below −60 and having a molecular mass less than 200 Da were selected as QSI candidates (these 22 structures are shown in Table S2 in the supplemental material). The cutoff value for the rerank score was set as −60 because most of the known QSIs that were docked earlier had scores below that value. The molecular mass cutoff value of 200 Da was arbitrarily determined in order to select for the most effective small-molecule inhibitors that can easily penetrate the bacteria cell. Thus, the 22 compounds selected were obtained and tested for its inhibition in vitro.

Inhibition assay with the P. aeruginosa lasB-gfp(ASV) strain.In the preliminary screen, the 22 selected QSI candidates were screened for their ability to inhibit QS-controlled green fluorescent protein (GFP) expression in the P. aeruginosa lasB-gfp(ASV) strain. Elastase (encoded by the lasB gene) is a virulence factor that is controlled by LasR and is therefore a good indicator for LasR activity (13). Five compounds, code named C1, F1, G1, H1, and F2 (Fig. 2), were found to inhibit LasR-controlled GFP expression in a dose-dependent manner without affecting cell growth. For ease of identification, each compound was designated with a short compound identification code based on its well position in the shipment in place of its standard IUPAC name.

Fig 2
  • Open in new tab
  • Download powerpoint
Fig 2

Structures of five QSI candidates and an additional compound found to be structurally similar to C1 and G1. Five QSIs are shown: 6-hydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (C1), 2-amino-3-(3-fluorophenyl)propanoic acid (F1), 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1), and 2-amino-3-hydroxy-3-phenylpropanoic acid (H1) and indole-3-carboxylic acid (F2). Compounds F1 and H1 are racemic, and asterisks within the structure denote the stereogenic centers within these compounds. Purine-2,6-diamine (404) was found through a structural similarity search of compounds with structures similar to that of G1.

The dose-response curves of these 5 QSI candidates when incubated with the P. aeruginosa PAO1 lasB-gfp(ASV) strain are shown in Fig. 3. GFP expression, which was measured in relative fluorescence units, was normalized by dividing the GFP value by the corresponding OD600 value measured at that time point. “Control” refers to the PAO1 strain grown without the presence of QSI, and as expected, it had the highest GFP-per-OD values. For these five compounds, dose-dependent inhibition of lasB-gfp expression was observed, i.e., the higher the concentration of QSI that was present, the greater the inhibition of gfp expression.

Fig 3
  • Open in new tab
  • Download powerpoint
Fig 3

Dose-response curves of 6-hydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (C1) (A), 2-amino-3-(3-fluorophenyl)propanoic acid (F1) (B), 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1) (C), 2-amino-3-hydroxy-3-phenylpropanoic acid (H1) (D), and indole-3-carboxylic acid (F2) (E) when incubated with the P. aeruginosa PAO1 lasB-gfp(ASV) strain. The key shows the concentrations of the respective QSI used. The experiments were performed in triplicate; a representative experiment is shown.

In order to map the interactions between the five QSI compounds and the residues within the LasR protein ligand-binding site, the software program LIGPLOT v. 4.5.3 (Fig. 4) (34) was used. This program provides a 2-dimensional map showing the hydrogen-bonding and hydrophobic interactions between atoms in the ligand and that of the binding partner. PyMOL was also used for 3D representations of these interaction maps (see Fig. S1 in the supplemental material).

Fig 4
  • Open in new tab
  • Download powerpoint
Fig 4

Interaction maps between residues within the LasR LBD and the following compounds: the native acyl homoserine lactone ligand, OdDHL (A); 6-hydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (C1) (B); 2-amino-3-(3-fluorophenyl) propanoic acid (F1) (C); 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1) (D); 2-amino-3-hydroxy-3-phenylpropanoic acid (H1) (E); and indole-3-carboxylic acid (F2) (F).

Table 2 summarizes the interactions between our 5 QSI compounds and residues within the LasR ligand binding domain (LBD). In a recent study, LasR was crystallized with the OdDHL LBD and other AHL agonists (37), which showed that LasR and OdDHL appeared to interact at residues Tyr 56, Trp 60, Arg 61, Asp 73, and Ser 129 (Fig. 5). Those results agree with the residues identified by LIGPLOT as determined in this study (Table 2).

View this table:
  • View inline
  • View popup
Table 2

Key residues within the LasR ligand binding pocket having hydrogen bonding interactions with OdDHL and the corresponding 5 QSI molecules

Fig 5
  • Open in new tab
  • Download powerpoint
Fig 5

Crystal structure model of the interactions between residues in the LasR ligand-binding pocket with the autoinducer molecule OdDHL. The wire mesh shows the electron density map. The image was adapted from reference 37 with permission of the publisher.

IC50 value comparisons of the five QSI candidates.The slope of the curve for each QSI was calculated based on its respective dose-response curves (from Fig. 3) and plotted against the log inhibitor concentration. The slope is indicative of the biosynthesis rate of GFP due to AHL induction. The half-maximal inhibitory concentrations (IC50s) of the five QSI candidates were calculated using the Graphpad Prism 6 software package (GraphPad Software Inc., California, USA). The IC50s of the 5 QSIs were mainly in the low micromolar range, with two compounds (C1 and G1) having values in the high nanomolar range (Fig. 6).

Fig 6
  • Open in new tab
  • Download powerpoint
Fig 6

The half-maximal inhibitory concentration (IC50) of 6-hydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (C1) (A), 2-amino-3-(3-fluorophenyl)propanoic acid (F1) (B), 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1) (C), 2-amino-3-hydroxy-3-phenylpropanoic acid (H1) (D), or indole-3-carboxylic acid (F2) (E). The minimum concentration of inhibitor was arbitrarily designated by the Graphpad PRISM software program to have a log[inhibitor] value of −10 (log) μM, since the logarithm of zero is undefined.

G1 had the lowest IC50, at 0.64 μM, meaning that this inhibitor was able to inhibit lasB-gfp expression with high efficiency. However, these compounds were not necessarily interacting directly with LasR, and therefore we used the heterologous E. coli strain containing the lasB-gfp(ASV) reporter to test for LasR-specific inhibition.

AHL competition assay using the heterologous E. coli lasB-gfp(ASV) strain.The five QSI candidates were tested for their specificities in inhibiting the LasR receptor by incubating these QSIs with the E. coli lasB-gfp(ASV) reporter strain. LasR is under the control of the Lac promoter and is constitutively expressed, and only LasR can activate gfp expression in this system. P. aeruginosa-based QS systems do not exist in E. coli, so exogenous OdDHL has to be added. Hence, this heterologous system provides a way to eliminate the contribution of QSI interaction with higher levels of control.

Of these 5 QSI candidates, only one compound, G1, was found to specifically inhibit LasR activity in the competition assay. The other four compounds did not show specific inhibition in the E. coli lasB-gfp(ASV) inhibition assay (see Fig. S2A to D in the supplemental material). Figure 7 shows the relative fluorescences of the E. coli lasB-gfp(ASV) strain in response to various concentrations of G1 and OdDHL. We see that increasing levels of OdDHL increase lasB-gfp expression, while increasing levels of QSI decrease it. The largest amount of relative fluorescence was observed for the condition of no G1 and 320 nM OdDHL (value = 1,340.4), and the smallest amount of relative fluorescence was seen for the condition of 100 μM G1 and no OdDHL (value = 438.1). The relative fluorescence values for the condition of 320 nM OdDHL with 100 μM G1 and the condition without OdDHL or G1 are 711.5 and 627.6, respectively. In the presence of 320 nM OdDHL, we have 46.9% inhibition by 100 μM G1 (compared to the value for the control without G1), while in the absence of OdDHL, we have only 30.2% inhibition by 100 μM G1 (compared to the control without G1).

Fig 7
  • Open in new tab
  • Download powerpoint
Fig 7

The response of the E. coli lasB-gfp(ASV) strain to various concentrations of 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1) and OdDHL. Relative fluorescence is normalized through dividing GFP values by OD600 values.

The results also show that even in the presence of 320 nM OdDHL, 1.56 μM G1 was sufficient in inhibiting OdDHL-LasR induction of gfp expression. If the OdDHL concentration were increased further, an outcompetition of G1 by OdDHL would eventually be seen, where lower levels of G1 would be ineffective in inhibiting gfp expression and only higher levels of G1 would be able to inhibit gfp expression. The 50% effective concentration (EC50) of OdDHL for LasR activation has been previously determined to be 10 nM (38), and therefore the range of OdDHL concentrations used for this assay is considered relatively high.

Effects of QSIs on rhl and pqs quorum-sensing systems.In order to address the problem of the specificity of our compounds, our five QSI compounds were tested to see if they had any effect on the rhl and pqs systems. The five QSIs were tested against a PAO1 wild type and a PAO1 lasR mutant harboring either the rhlA-gfp(ASV) bioreporter or the pqsA-gfp(ASV) bioreporter. The rhlA system is dependent on the RhlR/I system. By doing so, we were able to determine if a QSI is able to inhibit the other two QS systems (i.e., rhl and pqs) in a lasR-dependent/independent manner (Fig. 8).

Fig 8
  • Open in new tab
  • Download powerpoint
Fig 8

Expression of rhlA-gfp(ASV) (A) or pqsA-gfp(ASV) (B) in P. aeruginosa PAO1 wild type and a lasR mutant was measured when treated with 50 μM (each) QSI. Results are the average relative fluorescence values (GFP readings divided by OD600 values) from a single time point measurement corresponding to maximal induction of the reporters. Averages and standard deviations are from triplicate experiments.

G1 was found to inhibit rhlA-gfp expression in the wild-type PAO1 strain (23.1% inhibition) and also in the lasR mutant (46.5% inhibition) (Fig. 8A). The P. aeruginosa rhl QS system uses a signal molecule, BHL, which is structurally similar to OdDHL of the las QS system, to regulate gene expression. Hence, it is likely that G1 as an inhibitor of LasR could also inhibit RhlR in the absence of LasR. Our results suggest that G1 has a higher binding specificity for LasR than for RhlR.

G1 was observed to strongly inhibit pqsA-gfp expression in wild-type PAO1 (57.5% inhibition) and less strongly in the lasR mutant (24.4% inhibition) (Fig. 8B). Because the pqs QS system is positively regulated by the las system (39), inhibition of the las system by G1 would result in downregulation of pqs expression. This shows that G1 inhibits the las QS system specifically, and inhibition of pqs is through a LasR-dependent mechanism.

Interestingly, F1 was able to inhibit both the rhl and pqs systems in a LasR-independent manner. F1 inhibited rhlA-gfp expression in wild-type PAO1 by 61.7%, and in the lasR mutant it showed inhibition of 63.1% (Fig. 8A). F1 was also found to inhibit pqsA-gfp expression by 25.4% in the wild type and 39.4% in the lasR mutant (Fig. 8B). Our results suggest that F1 has a higher binding specificity for RhlR than for LasR.

Effect of G1 on extracellular DNA release in P. aeruginosa biofilms.The pqs QS system regulates release of extracellular DNA (eDNA), which is an important structure component for P. aeruginosa biofilms (40, 41). Using a slide biofilm assay, G1 was tested for its ability to reduce eDNA release in P. aeruginosa biofilms. Propidium iodide (PI) staining was used to stain and visualize eDNA. PI can stain both eDNA and dead cells; however, eDNA appears as string-like structures rather than the circular structures indicative of dead cells. A large amount of eDNA was observed in the substratum of P. aeruginosa PAO1 biofilms cultivated in ABTG medium (Fig. 9A and C), while less eDNA was observed in PAO1 biofilms cultivated in ABTG medium containing 10 μM G1 (Fig. 9B and D). This indicates that G1 was able to reduce eDNA release in P. aeruginosa.

Fig 9
  • Open in new tab
  • Download powerpoint
Fig 9

Biofilms of gfp-tagged PAO1 grown for 24 h either in ABTG medium (A and C) or ABTG medium containing 10 μM G1 (B and D) were stained with propidium iodide (PI). Images visualizing cells (green) and extracellular DNA (appearing red) were acquired by CLSM.

iTRAQ-based quantitative proteomic analysis.In order to study the proteins whose expression was downregulated in P. aeruginosa PAO1 as a result of G1 addition, iTRAQ was used as the labeling strategy for comparative quantitative proteomic analysis (performed with a false discovery rate below 1%). The following cutoffs were used for protein identification: unused protein score of at least 2 (i.e., 99% confidence of identification) and having more than 1 peptide identified. Using these cutoffs, 2,258 proteins were identified. Using a P value (115:114; (ratio of the protein's abundance in the G1-treated sample [115] to that in the untreated control [114]) cutoff of 0.05, 46 proteins were found to be significantly affected by G1; the abundance of 19 proteins was upregulated, while the abundance of 27 proteins was downregulated. In our study, upregulation was defined as an abundance (115:114 score) of at least 1.5, and downregulation was defined as an abundance value (115:114 score) below 0.66. Table 3 shows the 27 proteins whose abundances were significantly decreased in the G1-treated P. aeruginosa PAO1 strain versus those in the control PAO1 strain without G1 addition. Of these 27 proteins, 10 had been previously found to be QS regulated: protease IV, chitinase, hypothetical protein PA0572, pyoverdine synthetase D, pyoverdine chromophore synthetase PvdL, AmbE, probable nonribosomal peptide synthetase, chitin-binding protein CbpD precursor, conserved hypothetical protein PA0588, and cystathionine beta-synthase.

View this table:
  • View inline
  • View popup
Table 3

Proteins whose abundances in the P. aeruginosa PAO1 strain decreased significantly upon addition of 5-imino-4,6-dihydro-3H-1,2,3-triazolo[5,4-d]pyrimidin-7-one (G1)a

Nouwens et al. (42) performed a proteomic analysis of the extracellular proteins regulated by the las and rhl systems in P. aeruginosa (42). In that study, they found the expression of protease IV (PA4175) to be significantly downregulated in a las mutant; however, the amount of downregulation was not quantified. In our study, the abundance of protease IV (PA4175) was found to be 0.29 (fold change, −1.79). Protease IV is an extracellular protease that causes tissue damage in P. aeruginosa infections (43), and hence reducing the expression of this virulence factor may attenuate P. aeruginosa virulence. Garlic extract and 4-nitropyridine-N-oxide (4-NPO) were also found to reduce the expression of protease IV, by −6.9- and −20.7-fold, respectively (18).

Protease IV, also known as PrpL, is regulated by PvdS, which is an alternative sigma factor that regulates genes involved in siderophore biosynthesis (44). pvdS gene expression is regulated by the iron-sensing Fur repressor protein, such that pyoverdine is produced only under iron-limiting conditions (45, 46). Therefore, G1 may act through the interaction with the Fur protein to inhibit PvdS-regulated induction of pyoverdine synthesis genes.

In support of this idea, the abundances of two pyoverdine synthetases were found to be significantly reduced: pyoverdine synthetase D (pvdD; PA2399) by −0.89-fold and pyoverdine chromophore synthetase (pvdL; PA2424) by −0.73-fold. Pyoverdine is a siderophore that is required for iron acquisition, and siderophore-mediated signaling regulates the expression of several virulence factors (47). In a recent study by Taguchi et al. (48), a pvdL mutant of the Pseudomonas syringae pv. tabaci 6605 strain exhibited reduced virulence on host tobacco plants (48). The production of exopolysaccharide and AHL was reduced, and this pvdL mutant was less tolerant to antibiotic (chloramphenicol and spectinomycin) treatment. Further testing would be required to find out if G1 could affect the resistance of P. aeruginosa to antibiotics.

In the proteomics result for G1, elastase (lasB; PA3724), a virulence factor that is known to be induced by the las system, was not identified as downregulated. In another study, garlic extract and 4-NPO reduced the expression of elastase by −6.8- and −22.6-fold, respectively (18). Other QSIs, such as patulin and penicillic acid, reduced elastase expression by −7- and −12-fold, respectively, and in the P. aeruginosa PAO1 lasR mutant, elastase expression was decreased −13-fold (49). Hence, it was rather surprising not to find elastase on the list of downregulated proteins. Thus, we decided to use an enzymatic assay to test if elastase production was significantly reduced with the addition of G1.

Effect of G1 on production of elastase by P. aeruginosa.The metalloprotease elastase B is a las QS system-regulated virulence factor produced and excreted by P. aeruginosa (50). QSIs that inhibit the las QS system should be able to inhibit the production of elastase B. A standard enzymatic assay was used to test whether G1 could inhibit the elastase activities of P. aeruginosa cultures. The result showed that addition of G1 to P. aeruginosa PAO1 cultures at 50 and 100 μM could almost abolish elastase production within a 2-h cultivation period (Fig. 10), matching the levels of a P. aeruginosa PAO1 lasI rhlI mutant. This P. aeruginosa PAO1 lasI rhlI mutant is deficient in quorum-sensing and is used as a negative control. The amount of elastase produced by P. aeruginosa upon exposure to G1 was similar to that for this negative control, which indicates that G1 was efficient in inhibiting elastase production.

Fig 10
  • Open in new tab
  • Download powerpoint
Fig 10

Effect of G1 on the elastase activities of P. aeruginosa cultures. Elastase activities of P. aeruginosa culture supernatants were measured by using the EnzChekElastase assay kit (Invitrogen). Fluorescence was recorded every 6 min for 180 min by using a Tecan Infinite 200 Pro plate reader (excitation at 490 nm, emission at 520 nm). The P. aeruginosa PAO1 lasI rhlI strain served as a negative control.

DISCUSSION

In a previous study by Yang et al. (27), 147 compounds were screened based on structural similarity to the ligand OdDHL. Six top-scoring hits were identified and tested for QSI activity; of these, three were found to have dose-dependent inhibition of QS-related gene expression and associated phenotypes. In the present study, we have used DG-AMMOS to enhance in silico QSI discovery. One advantage of using DG-AMMOS, rather than relying on structural similarity to the ligand of interest, is the avoidance of rational bias in the screening process, therefore allowing the detection of lead compounds that may not be able to be identified rationally. Hence, it is possible that DG-AMMOS can be extended to the conversion of larger compound libraries (e.g., 10,000-compound libraries and combinatorial chemistry libraries) and allows the discovery of new compounds that may have little structural similarity to QSIs or AHLs yet possess QSI properties.

SB-VS has been used extensively in the pharmaceutical industry, famous examples being Relenza, an anti-influenza drug that targets sialidase (51), and Viracept, a human immunodeficiency virus protease inhibitor (52). In recent years, SB-VS approaches have also been used in the search for novel QSIs, and here are a few recent examples: (i) discovery of hamamelitannin, a natural compound from Hamamelis virginiana that inhibits QS in drug-resistant Staphylococcus aureus and Staphylococcus epidermidis (53); (ii) identification of novel AI-2 QS inhibitors of Vibrio harveyi by SB-VS with the crystal structure of LuxP (54); (iii) discovery of a compound from Melia dubia bark extract which could inhibit the QS regulator SdiA, present in uropathogenic E. coli (UPEC) (55); (iv) discovery of five QSIs from an SB-VS of 1,920 natural compounds against the LasR and RhlR receptor proteins (56); and (v) discovery of 5 inducers and 3 inhibitors of LasR through a SB-VS of 800,000-plus compounds from the Chembridge library through a pharmacophore-based approach for compounds similar to OdDHL (57).

One major limitation of SB-VS is the problem of false positives and false negatives predicted by the docking software. However, with the development of newer and better algorithms, the problem of false hits may be minimized. Also, the aim may not be to eliminate false positives entirely but to reduce them to a tolerable level, the reason being that false positives may lead to the discovery of novel molecular interactions. As such, the cutoff of a −60 rerank score that was used in our study for identifying potential QSI candidates might have been too stringent, and a higher value (i.e., less negative) could have been used instead so as to increase the number of potential hits. However, using a less stringent cutoff would increase the number of false positives, and this trade-off between the number of potential leads and the number of false positives must be considered for all SB-VS studies.

On the whole, SB-VS methods provide a faster and cheaper alternative to high-throughput screening (HTS) approaches for several reasons. First, if the search strategy in SB-VS is restricted to commercially available compound libraries, the lead compounds identified through SB-VS can be purchased easily and one does not need to undertake a costly chemical synthesis process. Second, SB-VS can be used to dock known drugs or natural plant derivatives, which would be likely to have lower toxicities than compounds synthesized through combinatorial chemistry. Thus, compounds identified through screening of known drugs/natural product libraries can avoid failure in the in vitro and in vivo testing stages due to toxicity. Last, SB-VS is able to first narrow down the list of compounds to be tested before proceeding with actual in vitro tests for efficacy, and this would greatly reduce costs compared to conventional HTS methods, where all compounds have to be tested.

In this study, we have shown that structure-based virtual screening is a viable and effective means for the discovery of novel QS inhibitors. From a library of 3,040 natural compounds, 22 compounds met selection criteria and were tested for biological activity. Five of these compounds were found to have dose-dependent inhibition of the las QS system. However, only G1 was shown to have dose-dependent inhibition of lasB-gfp in both the P. aeruginosa and E. coli strains, indicating its specificity for the LasR protein. Among the five QSI candidates, it had the lowest IC50 at 0.64 μM.

G1 was also able to delay the induction of the rhl QS system (data not shown). G1 showed some inhibition of the rhl QS system; perhaps it either has very weak binding affinity or allosteric effects. This may be due to the presence of the homoserine lactone ring present in both the LasR ligand, OdDHL, and the RhlR ligand, BHL. Studies have shown that the lactone ring is important for interaction with the LasR binding pocket (38). Presumably, an RhlR structure would be very useful to help understand the differences in the binding pockets and hence the binding of compounds like G1. However, the crystal structure of RhlR is unavailable, so homology modeling may be used to generate a putative structure for docking studies.

Besides the rhl system, G1 was also found to repress the PQS system. Previous studies have shown that the las QS system positively regulates the pqs QS system (39), and the results of our study suggest that G1 represses expression of the PQS system through inhibition of the las QS system. The pqs QS system regulates release of eDNA, which is an important structural component for P. aeruginosa biofilms (40, 41). As such, we found that G1 was able to reduce the amount of eDNA being released by P. aeruginosa. Previous studies have shown that eDNA is essential for biofilm formation (58), and further investigation is necessary to study the potential of G1 in the prevention of biofilm formation.

It is not yet clear why the other four QSIs (C1, F1, H1, and F2) were able to inhibit gfp expression in the P. aeruginosa lasB-gfp system but not in the E. coli lasB-gfp system. This is puzzling because they were identified by molecular docking against the LasR LBD and were shown by LIGPLOT to have specific H-bonding interactions with residues within the LasR ligand binding pocket. Therefore, these compounds should in theory specifically target LasR. This could indicate two things: (i) that these four QSIs do not bind specifically to LasR and instead inhibit gfp expression indirectly in the P. aeruginosa reporter strain through other pathways that affect the las QS pathway or (ii) that E. coli has molecular machinery that is able to either degrade or selectively pump these compounds out of the cell.

These results suggest that the structure of G1 may be important for its ability to interact with and inhibit LasR specifically. If we compare the structures of G1 and C1 (Fig. 2), we see that their structures are very similar, the difference being the presence of an additional imino group on G1. Hence, it is interesting that G1 (but not C1) was able to inhibit lasB-gfp(ASV) in the E. coli system despite their structural similarity. In fact, there are other compounds similar to G1 that may have been missed. A structure subgroup search for compounds within the Natural Derivatives Library found the molecule 404 (Fig. 2) to be similar in size and structure to G1. However, molecule 404 had a docking rerank score of −5.03 and was therefore excluded by the −60 cutoff score we used. As such, the cutoff rerank score of −60 that was used may have been too stringent, and we may have missed hits by using that value. Hence, the idea should be to use a cutoff for excluding low-scoring compounds but not to use it for identifying top-scoring hits; a larger starting pool of molecules would then be tested for in vitro inhibition efficacy, and this may result in a better hit rate.

Another interesting result was that F1 was able to inhibit both the rhl and pqs systems in a LasR-independent manner. This may mean that F1 may be interacting with a QS component distinct from LasR yet affects the rhl and pqs systems. Further studies will be done to investigate the mechanisms by which F1 inhibits QS in P. aeruginosa and its potential as an antivirulence compound.

These results emphasize the application of SB-VS for the discovery of target-specific inhibitors, and future work includes the extension of this method to new molecular targets. A future aim would be to work alongside chemists to develop new QSI compounds and to perform quantitative structure-activity relationship (QSAR) studies to aid in our knowledge of rational drug design.

ACKNOWLEDGMENTS

This research was supported by the National Research Foundation and Ministry of Education Singapore under its Research Centre of Excellence Programme and a Start-up Grant (M4330002.C70) from Nanyang Technological University, Singapore.

FOOTNOTES

    • Received 7 May 2013.
    • Returned for modification 7 June 2013.
    • Accepted 24 August 2013.
    • Accepted manuscript posted online 3 September 2013.
  • Supplemental material for this article may be found at http://dx.doi.org/10.1128/AAC.00955-13.

  • Copyright © 2013, American Society for Microbiology. All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Fuqua WC,
    2. Winans SC,
    3. Greenberg EP
    . 1994. Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J. Bacteriol. 176:269–275.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Miller MB,
    2. Bassler BL
    . 2001. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55:165–199.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Bassler BL,
    2. Losick R
    . 2006. Bacterially speaking. Cell 125:237–246.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Obritsch MD,
    2. Fish DN,
    3. MacLaren R,
    4. Jung R
    . 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353–1364.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Finnan S,
    2. Morrissey JP,
    3. O'Gara F,
    4. Boyd EF
    . 2004. Genome diversity of Pseudomonas aeruginosa isolates from cystic fibrosis patients and the hospital environment. J. Clin. Microbiol. 42:5783–5792.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Fuqua C,
    2. Parsek MR,
    3. Greenberg EP
    . 2001. Regulation of gene expression by cell-to-cell communication: acyl-homoserine lactone quorum sensing. Annu. Rev. Genet. 35:439–468.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Pearson JP,
    2. Gray KM,
    3. Passador L,
    4. Tucker KD,
    5. Eberhard A,
    6. Iglewski BH,
    7. Greenberg EP
    . 1994. Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes. Proc. Natl. Acad. Sci. U. S. A. 91:197–201.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Ochsner UA,
    2. Reiser J
    . 1995. Autoinducer-mediated regulation of rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 92:6424–6428.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Gambello MJ,
    2. Iglewski BH
    . 1991. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J. Bacteriol. 173:3000–3009.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Gambello MJ,
    2. Kaye S,
    3. Iglewski BH
    . 1993. LasR of Pseudomonas aeruginosa is a transcriptional activator of the alkaline protease gene (apr) and an enhancer of exotoxin A expression. Infect. Immun. 61:1180–1184.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Passador L,
    2. Cook JM,
    3. Gambello MJ,
    4. Rust L,
    5. Iglewski BH
    . 1993. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. Science 260:1127–1130.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Pesci EC,
    2. Milbank JBJ,
    3. Pearson JP,
    4. McKnight S,
    5. Kende AS,
    6. Greenberg EP,
    7. Iglewski BH
    . 1999. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 96:11229–11234.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Pesci EC,
    2. Pearson JP,
    3. Seed PC,
    4. Iglewski BH
    . 1997. Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 179:3127–3132.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Hentzer M,
    2. Wu H,
    3. Andersen JB,
    4. Riedel K,
    5. Rasmussen TB,
    6. Bagge N,
    7. Kumar N,
    8. Schembri MA,
    9. Song Z,
    10. Kristoffersen P,
    11. Manefield M,
    12. Costerton JW,
    13. Molin S,
    14. Eberl L,
    15. Steinberg P,
    16. Kjelleberg S,
    17. Høiby N,
    18. Givskov M
    . 2003. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22:3803–3815.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Hentzer M,
    2. Givskov M
    . 2003. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J. Clin. Invest. 112:1300–1307.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Fletcher MP,
    2. Diggle SP,
    3. Camara M,
    4. Williams P
    . 2007. Biosensor-based assays for PQS, HHQ and related 2-alkyl-4-quinolone quorum sensing signal molecules. Nat. Protoc. 2:1254–1262.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Müh U,
    2. Schuster M,
    3. Heim R,
    4. Singh A,
    5. Olson ER,
    6. Greenberg EP
    . 2006. Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob. Agents Chemother. 50:3674–3679.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Rasmussen TB,
    2. Bjarnsholt T,
    3. Skindersoe ME,
    4. Hentzer M,
    5. Kristoffersen P,
    6. Köte M,
    7. Nielsen J,
    8. Eberl L,
    9. Givskov M
    . 2005. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J. Bacteriol. 187:1799–1814.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Rasmussen TB,
    2. Givskov M
    . 2006. Quorum-sensing inhibitors as anti-pathogenic drugs. Int. J. Med. Microbiol. 296:149–161.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Kalia D,
    2. Merey G,
    3. Nakayama S,
    4. Zheng Y,
    5. Zhou J,
    6. Luo Y,
    7. Guo M,
    8. Roembke BT,
    9. Sintim HO
    . 2013. Nucleotide, c-di-GMP, c-di-AMP, cGMP, cAMP, (p)ppGpp signaling in bacteria and implications in pathogenesis. Chem. Soc. Rev. 42:305–341.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Cornelis P,
    2. Aendekerk S
    . 2004. A new regulator linking quorum sensing and iron uptake in Pseudomonas aeruginosa. Microbiology 150:752–756.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Jensen V,
    2. Lons D,
    3. Zaoui C,
    4. Bredenbruch F,
    5. Meissner A,
    6. Dieterich G,
    7. Munch R,
    8. Haussler S
    . 2006. RhlR expression in Pseudomonas aeruginosa is modulated by the Pseudomonas quinolone signal via PhoB-dependent and -independent pathways. J. Bacteriol. 188:8601–8606.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Shoichet BK
    . 2004. Virtual screening of chemical libraries. Nature 432:862–865.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Ghosh S,
    2. Nie A,
    3. An J,
    4. Huang Z
    . 2006. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem. Biol. 10:194–202.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Bottomley MJ,
    2. Muraglia E,
    3. Bazzo R,
    4. Carfì A
    . 2007. Molecular insights into quorum sensing in the human pathogen Pseudomonas aeruginosa from the structure of the virulence regulator LasR bound to its autoinducer. J. Biol. Chem. 282:13592–13600.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Vannini A,
    2. Volpari C,
    3. Gargioli C,
    4. Muraglia E,
    5. Cortese R,
    6. De Francesco R,
    7. Neddermann P,
    8. Di Marco S
    . 2002. The crystal structure of the quorum sensing protein TraR bound to its autoinducer and target DNA. EMBO J. 21:4393–4401.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Yang L,
    2. Rybtke MT,
    3. Jakobsen TH,
    4. Hentzer M,
    5. Bjarnsholt T,
    6. Givskov M,
    7. Tolker-Nielsen T
    . 2009. Computer-aided identification of recognized drugs as Pseudomonas aeruginosa quorum-sensing inhibitors. Antimicrob. Agents Chemother. 53:2432–2443.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Dunkel M,
    2. Fullbeck M,
    3. Neumann S,
    4. Preissner R
    . 2006. SuperNatural: a searchable database of available natural compounds. Nucleic Acids Res. 34:D678–D683.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Goede A,
    2. Dunkel M,
    3. Mester N,
    4. Frommel C,
    5. Preissner R
    . 2005. SuperDrug: a conformational drug database. Bioinformatics 21:1751–1753.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. Lagorce D,
    2. Pencheva T,
    3. Villoutreix BO,
    4. Miteva MA
    . 2009. DG-AMMOS: a new tool to generate 3D conformation of small molecules using distance geometry and automated molecular mechanics optimization for in silico screening. BMC Chem. Biol. 9:6. doi:10.1186/1472-6769-9-6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Thomsen R,
    2. Christensen MH
    . 2006. MolDock: a new technique for high-accuracy molecular docking. J. Med. Chem. 49:3315–3321.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Friesner RA,
    2. Banks JL,
    3. Murphy RB,
    4. Halgren TA,
    5. Klicic JJ,
    6. Daniel T,
    7. Repasky MP,
    8. Knoll EH,
    9. Shelley M,
    10. Perry JK
    . 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47:1739–1749.
    OpenUrlCrossRef
  33. 33.↵
    1. Jain AN
    . 2003. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J. Med. Chem. 46:499–511.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Wallace AC,
    2. Laskowski RA,
    3. Thornton JM
    . 1995. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8:127–134.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Andersen JB,
    2. Sternberg C,
    3. Poulsen LK,
    4. Bjørn SP,
    5. Givskov M,
    6. Molin S
    . 1998. New unstable variants of green fluorescent protein for studies of transient gene expression in bacteria. Appl. Environ. Microbiol. 64:2240–2246.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Liu Y,
    2. Yang L,
    3. Molin S
    . 2010. Synergistic activities of an efflux pump inhibitor and iron chelators against Pseudomonas aeruginosa growth and biofilm formation. Antimicrob. Agents Chemother. 54:3960–3963.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Zou Y,
    2. Nair SK
    . 2009. Molecular basis for the recognition of structurally distinct autoinducer mimics by the Pseudomonas aeruginosa LasR quorum-sensing signaling receptor. Chem. Biol. 16:961–970.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Geske GD,
    2. O'Neill JC,
    3. Miller DM,
    4. Mattmann ME,
    5. Blackwell HE
    . 2007. Modulation of bacterial quorum sensing with synthetic ligands: systematic evaluation of N-acylated homoserine lactones in multiple species and new insights into their mechanisms of action. J. Am. Chem. Soc. 129:13613–13625.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. McGrath S,
    2. Wade DS,
    3. Pesci EC
    . 2004. Dueling quorum sensing systems in Pseudomonas aeruginosa control the production of the Pseudomonas quinolone signal (PQS). FEMS Microbiol. Lett. 230:27–34.
    OpenUrlCrossRefPubMedWeb of Science
  40. 40.↵
    1. Allesen-Holm M,
    2. Barken KB,
    3. Yang L,
    4. Klausen M,
    5. Webb JS,
    6. Kjelleberg S,
    7. Molin S,
    8. Givskov M,
    9. Tolker-Nielsen T
    . 2006. A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms. Mol. Microbiol. 59:1114–1128.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Yang L,
    2. Barken KB,
    3. Skindersoe ME,
    4. Christensen AB,
    5. Givskov M,
    6. Tolker-Nielsen T
    . 2007. Effects of iron on DNA release and biofilm development by Pseudomonas aeruginosa. Microbiology 153:1318–1328.
    OpenUrlCrossRefPubMedWeb of Science
  42. 42.↵
    1. Nouwens AS,
    2. Beatson SA,
    3. Whitchurch CB,
    4. Walsh BJ,
    5. Schweizer HP,
    6. Mattick JS,
    7. Cordwell SJ
    . 2003. Proteome analysis of extracellular proteins regulated by the las and rhl quorum sensing systems in Pseudomonas aeruginosa PAO1. Microbiology 149:1311–1322.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Engel LS,
    2. Hill JM,
    3. Caballero AR,
    4. Green LC,
    5. O'Callaghan RJ
    . 1998. Protease IV, a unique extracellular protease and virulence factor from Pseudomonas aeruginosa. J. Biol. Chem. 273:16792–16797.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Wilderman PJ,
    2. Vasil AI,
    3. Johnson Z,
    4. Wilson MJ,
    5. Cunliffe HE,
    6. Lamont IL,
    7. Vasil ML
    . 2001. Characterization of an endoprotease (PrpL) encoded by a PvdS-regulated gene in Pseudomonas aeruginosa. Infect. Immun. 69:5385–5394.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Cunliffe HE,
    2. Merriman TR,
    3. Lamont IL
    . 1995. Cloning and characterization of pvdS, a gene required for pyoverdine synthesis in Pseudomonas aeruginosa: PvdS is probably an alternative sigma factor. J. Bacteriol. 177:2744–2750.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Leoni L,
    2. Ciervo A,
    3. Orsi N,
    4. Visca P
    . 1996. Iron-regulated transcription of the pvdA gene in Pseudomonas aeruginosa: effect of Fur and PvdS on promoter activity. J. Bacteriol. 178:2299–2313.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. Lamont IL,
    2. Beare PA,
    3. Ochsner U,
    4. Vasil AI,
    5. Vasil ML
    . 2002. Siderophore-mediated signaling regulates virulence factor production in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 99:7072–7077.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Taguchi F,
    2. Suzuki T,
    3. Inagaki Y,
    4. Toyoda K,
    5. Shiraishi T,
    6. Ichinose Y
    . 2010. The siderophore pyoverdine of Pseudomonas syringae pv. tabaci 6605 is an intrinsic virulence factor in host tobacco infection. J. Bacteriol. 192:117–126.
    OpenUrlAbstract/FREE Full Text
  49. 49.↵
    1. Rasmussen TB,
    2. Skindersoe ME,
    3. Bjarnsholt T,
    4. Phipps RK,
    5. Christensen KB,
    6. Jensen PO,
    7. Andersen JB,
    8. Koch B,
    9. Larsen TO,
    10. Hentzer M
    . 2005. Identity and effects of quorum-sensing inhibitors produced by Penicillium species. Microbiology 151:1325–1340.
    OpenUrlCrossRefPubMedWeb of Science
  50. 50.↵
    1. Pearson JP,
    2. Pesci EC,
    3. Iglewski BH
    . 1997. Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J. Bacteriol. 179:5756–5767.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. von Itzstein M,
    2. Wu WY,
    3. Kok GB,
    4. Pegg MS,
    5. Dyason JC,
    6. Jin B,
    7. Van Phan T,
    8. Smythe ML,
    9. White HF,
    10. Oliver SW
    . 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418–423.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    1. Kaldor SW,
    2. Kalish VJ,
    3. Davies JF,
    4. Shetty BV,
    5. Fritz JE,
    6. Appelt K,
    7. Burgess JA,
    8. Campanale KM,
    9. Chirgadze NY,
    10. Clawson DK
    . 1997. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:3979–3985.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Kiran MD,
    2. Adikesavan NV,
    3. Cirioni O,
    4. Giacometti A,
    5. Silvestri C,
    6. Scalise G,
    7. Ghiselli R,
    8. Saba V,
    9. Orlando F,
    10. Shoham M
    . 2008. Discovery of a quorum-sensing inhibitor of drug-resistant staphylococcal infections by structure-based virtual screening. Mol. Pharmacol. 73:1578–1586.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Li M,
    2. Ni N,
    3. Chou HT,
    4. Lu CD,
    5. Tai PC,
    6. Wang B
    . 2008. Structure-based discovery and experimental verification of novel AI-2 quorum sensing inhibitors against Vibrio harveyi. ChemMedChem 3:1242–1249.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Ravichandiran V,
    2. Shanmugam K,
    3. Anupama K,
    4. Thomas S,
    5. Princy A
    . 2012. Structure-based virtual screening for plant-derived SdiA-selective ligands as potential antivirulent agents against uropathogenic Escherichia coli. Eur. J. Med. Chem. 48:200–205.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Annapoorani A,
    2. Umamageswaran V,
    3. Parameswari R,
    4. Pandian SK,
    5. Ravi AV
    . 2012. Computational discovery of putative quorum sensing inhibitors against LasR and RhlR receptor proteins of Pseudomonas aeruginosa. J. Comput. Aided Mol. Des. 26:1067–1077.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Skovstrup S,
    2. Quement L,
    3. Thordal S,
    4. Hansen T,
    5. Jakobsen TH,
    6. Harmsen M,
    7. Tolker-Nielsen T,
    8. Nielsen TE,
    9. Givskov M,
    10. Taboureau O
    . 2013. Identification of LasR ligands through a virtual screening approach. ChemMedChem 8:157–163.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Whitchurch CB,
    2. Tolker-Nielsen T,
    3. Ragas PC,
    4. Mattick JS
    . 2002. Extracellular DNA required for bacterial biofilm formation. Science 295:1487.
    OpenUrlFREE Full Text
  59. 59.
    1. Hentzer M,
    2. Riedel K,
    3. Rasmussen TB,
    4. Heydorn A,
    5. Andersen JB,
    6. Parsek MR,
    7. Rice SA,
    8. Eberl L,
    9. Molin S,
    10. Høiby N
    . 2002. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148:87–102.
    OpenUrlCrossRefPubMedWeb of Science
  60. 60.
    1. Stintzi A,
    2. Evans K,
    3. Meyer J,
    4. Poole K
    . 1998. Quorum-sensing and siderophore biosynthesis in Pseudomonas aeruginosa: lasRllasI mutants exhibit reduced pyoverdine biosynthesis. FEMS Microbiol. Lett. 166:341–345.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.
    1. Whiteley M,
    2. Lee KM,
    3. Greenberg E
    . 1999. Identification of genes controlled by quorum sensing in Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 96:13904–13909.
    OpenUrlAbstract/FREE Full Text
  62. 62.
    1. Wagner VE,
    2. Bushnell D,
    3. Passador L,
    4. Brooks AI,
    5. Iglewski BH
    . 2003. Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J. Bacteriol. 185:2080–2095.
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Winsor GL,
    2. Lam DK,
    3. Fleming L,
    4. Lo R,
    5. Whiteside MD,
    6. Yu NY,
    7. Hancock RE,
    8. Brinkman FS
    . 2011. Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes. Nucleic Acids Res. 39:D596–D600.
    OpenUrlCrossRefPubMedWeb of Science
  64. 64.↵
    1. Clark DJ,
    2. Maaløe O
    . 1967. DNA replication and the division cycle in Escherichia coli. J. Mol. Biol. 23:99–112.
    OpenUrlCrossRefWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Identification of Five Structurally Unrelated Quorum-Sensing Inhibitors of Pseudomonas aeruginosa from a Natural-Derivative Database
Sean Yang-Yi Tan, Song-Lin Chua, Yicai Chen, Scott A. Rice, Staffan Kjelleberg, Thomas E. Nielsen, Liang Yang, Michael Givskov
Antimicrobial Agents and Chemotherapy Oct 2013, 57 (11) 5629-5641; DOI: 10.1128/AAC.00955-13

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of Five Structurally Unrelated Quorum-Sensing Inhibitors of Pseudomonas aeruginosa from a Natural-Derivative Database
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Identification of Five Structurally Unrelated Quorum-Sensing Inhibitors of Pseudomonas aeruginosa from a Natural-Derivative Database
Sean Yang-Yi Tan, Song-Lin Chua, Yicai Chen, Scott A. Rice, Staffan Kjelleberg, Thomas E. Nielsen, Liang Yang, Michael Givskov
Antimicrobial Agents and Chemotherapy Oct 2013, 57 (11) 5629-5641; DOI: 10.1128/AAC.00955-13
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596